(Q34514813)

2 August 2017

1 reference

title

B-cell targeting in rheumatoid arthritis and other autoimmune diseases (English)

1 reference

2 August 2017

1 reference

Jonathan C W Edwards

1

1 reference

PubMed ID

16622478

2 August 2017

Geraldine Cambridge

series ordinal

2

1 reference

2 August 2017

1 May 2006

1 reference

Nature Reviews Immunology

2 August 2017

1 reference

2 August 2017

6

1 reference

2 August 2017

5

1 reference

2 August 2017

394-403

1 reference

Bm1-Bm5 classification of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjögren's syndrome.

2 August 2017

1 reference

Complement activation determines the therapeutic activity of rituximab in vivo.

21 January 2018

1 reference

ON THE OCCURRENCE OF A FACTOR IN HUMAN SERUM ACTIVATING THE SPECIFIC AGGLUTINATION OF SHEEP BLOOD CORPUSCLES

21 January 2018

1 reference

Rheumatoid arthritis: a disease of T-lymphocyte/macrophage immunoregulation

31 March 2020

1 reference

Hereditary periodic fever syndromes

31 March 2020

1 reference

Association of the B-cell alloantigen DRw4 with rheumatoid arthritis

31 March 2020

1 reference

Ankylosing spondylitis and HL-A 27.

31 March 2020

1 reference

The role of complement in the development of systemic lupus erythematosus

31 March 2020

1 reference

NOD2/CARD15, TLR4 and CD14 mutations in Scottish and Irish Crohn's disease patients: evidence for genetic heterogeneity within Europe?

31 March 2020

1 reference

Do self-perpetuating B lymphocytes drive human autoimmune disease?

31 March 2020

1 reference

From T to B and back again: positive feedback in systemic autoimmune disease

31 March 2020

1 reference

New treatments for SLE: cell-depleting and anti-cytokine therapies

31 March 2020

1 reference

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

31 March 2020

1 reference

Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis

31 March 2020

1 reference

Pathogenic roles of B cells in human autoimmunity; insights from the clinic

31 March 2020

1 reference

The BAFF/APRIL system: an important player in systemic rheumatic diseases

31 March 2020

1 reference

BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF

31 March 2020

1 reference

Memory B-cell clones and the diversity of their members

31 March 2020

1 reference

The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity

31 March 2020

1 reference

Feedback regulation by IgG antibodies.

31 March 2020

1 reference

Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors

31 March 2020

1 reference

Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells

31 March 2020

1 reference

Rheumatoid arthritis: the predictable effect of small immune complexes in which antibody is also antigen

31 March 2020

1 reference

Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis

31 March 2020

1 reference

Fibroblast biology. Development and differentiation of synovial fibroblasts in arthritis

31 March 2020

1 reference

How important are T cells in chronic rheumatoid synovitis?

31 March 2020

1 reference

Differential distribution of Fc gamma RIIIa in normal human tissues and co-localization with DAF and fibrillin-1: implications for immunological microenvironments.

31 March 2020

1 reference

Induction of tumor necrosis factor alpha production by adhered human monocytes: a key role for Fcgamma receptor type IIIa in rheumatoid arthritis

31 March 2020

1 reference

How antibodies to a ubiquitous cytoplasmic enzyme may provoke joint-specific autoimmune disease

31 March 2020

1 reference

Rituximab: ongoing and future clinical development

31 March 2020

1 reference

The biology of CD20 and its potential as a target for mAb therapy

31 March 2020

1 reference

The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy

31 March 2020

1 reference

The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.

31 March 2020

1 reference

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

31 March 2020

1 reference

Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy

31 March 2020

1 reference

Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes

31 March 2020

1 reference

Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion

31 March 2020

1 reference

Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis

31 March 2020

1 reference

Interstitial pneumonitis following rituximab therapy for immune thrombocytopenic purpura (ITP)

31 March 2020

1 reference

Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells

31 March 2020

1 reference

Improvement of refractory rheumatoid arthritis after depletion of B cells

31 March 2020

1 reference

T cell activation in rheumatoid synovium is B cell dependent

31 March 2020

1 reference

Regeneration of the immunoglobulin heavy-chain repertoire after transient B-cell depletion with an anti-CD20 antibody

31 March 2020

1 reference

Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse

31 March 2020

1 reference

Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis

31 March 2020

1 reference

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.

31 March 2020

1 reference

The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura

31 March 2020

1 reference

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura

31 March 2020

1 reference

An open study of B lymphocyte depletion in systemic lupus erythematosus

31 March 2020

1 reference

Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus

31 March 2020

1 reference

Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone

31 March 2020

1 reference

B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.

31 March 2020

1 reference

Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy

31 March 2020

1 reference

Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis

31 March 2020

1 reference

Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab

31 March 2020

1 reference

31 March 2020

1 reference

Chronic neuropathy with IgM anti-ganglioside antibodies: lack of long term response to rituximab

31 March 2020

1 reference

Rituximab for myasthenia gravis developing after bone marrow transplant

31 March 2020

1 reference

Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma

31 March 2020

1 reference

Rituximab in the treatment of dermatomyositis: an open-label pilot study

31 March 2020

1 reference

Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease

31 March 2020

1 reference

Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus

31 March 2020

1 reference

Efficacy and safety of rituximab in type II mixed cryoglobulinemia

31 March 2020

1 reference

Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura

31 March 2020

1 reference

Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study

31 March 2020

1 reference

Rituximab in the treatment of acquired factor VIII inhibitors

31 March 2020

1 reference

Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis

31 March 2020

1 reference

Effective suppression of cerebrospinal fluid B cells by rituximab and cyclophosphamide in progressive multiple sclerosis

31 March 2020

1 reference

The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion.

31 March 2020

1 reference

Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis

31 March 2020

1 reference

A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma

31 March 2020

1 reference

CD22 regulates B cell receptor-mediated signals via two domains that independently recruit Grb2 and SHP-1

31 March 2020

1 reference

Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations

31 March 2020

1 reference

TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS

31 March 2020

1 reference

TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease

31 March 2020

1 reference

Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF.

31 March 2020

1 reference

Generation and characterization of LymphoStat‐B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator

31 March 2020

1 reference

BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus.

31 March 2020

1 reference

Rationale for new treatments aimed at IgE immunomodulation

31 March 2020

1 reference

Cutting edge: the B cell chemokine CXC chemokine ligand 13/B lymphocyte chemoattractant is expressed in the high endothelial venules of lymph nodes and Peyer's patches and affects B cell trafficking across high endothelial venules

31 March 2020

1 reference

Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients

31 March 2020

1 reference

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition

31 March 2020

1 reference

Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling.

31 March 2020

1 reference

Targeting Syk as a treatment for allergic and autoimmune disorders

31 March 2020

1 reference

BCMA is essential for the survival of long-lived bone marrow plasma cells

31 March 2020

1 reference

LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRI1838

1 reference

release_kcfau4xqz5d2xmxalvytjka7iy

2 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/kcfau4xqz5d2xmxalvytjka7iy

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

16622478

1 reference

PubMed ID

16622478